Tebotelimab

Phase 1Monoclonal antibody

MMacroGenics

Tebotelimab is one of 6 biologic programs targeting Metastatic Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic NeoplasmActive, not recruiting

Metastatic NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Metastatic Neoplasm

#DrugCompanyPhaseTrials

Libtayo

Yervoy

Gilotrif

Cediranib

Margetuximab

TTerSera Therapeutics LLC

Phase 1

1 6

Tebotelimab

MMacroGenics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chemotherapy1 trial

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Completed·MMacroGenics·Phase 2/3·NCT04082364·82 enrolled

Head and Neck Cancer1 trial

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Terminated·MMacroGenics·Phase 2·NCT04634825·62 enrolled

Metastatic Neoplasm1 trial

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Completed·MMacroGenics·Phase 1·NCT03219268·277 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tebotelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tebotelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tebotelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MacroGenics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: MMacroGenics

Tebotelimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chemotherapy1 trial

Head and Neck Cancer1 trial

Metastatic Neoplasm1 trial

References

Drug Info

Quick Facts

Related News